阿利吉仑治疗中青年高血压的效果及其对患者RASS的影响

发布时间：2018-12-11 06:42

【摘要】：目的观察阿利吉仑治疗中青年高血压的临床效果以及对患者肾素-血管紧张素-醛固酮系统(RAAS)的影响。方法将106例中青年高血压患者随机分为观察组和对照组各53例,观察组口服阿利吉仑,对照组口服依那普利。两组均4周为1个疗程,共观察2个疗程。治疗前及治疗后第8周行动脉血压监测,治疗前及治疗后第4、8周取血检测血浆肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD),观察治疗期间降压药物不良反应,治疗前及治疗后半年行心脏彩色超声检查。结果观察组收缩压下降值、舒张压下降值、脉压下降值和收缩压谷峰比值高于对照组,差异有统计学意义(P均0.05)。治疗第4周,观察组血浆PRA、AngⅡ、ALD水平低于治疗前(P均0.05);治疗第8周,两组血浆PRA、AngⅡ、ALD水平均低于治疗前,且观察组低于对照组(P均0.05)。治疗后半年时,观察组舒张末期室间隔厚度、左心室内径、左心室后壁厚度及A/E小于对照组,左心室射血分数高于对照组,差异有统计学意义(P均0.05)。两组药物不良反应发生率比较,差异无统计学意义。结论阿利吉仑调控中青年高血压效果较好,能明显阻断RAAS活性,保护靶器官,且安全性良好。
[Abstract]:Objective to observe the clinical effect of alligilun in the treatment of young and middle-aged hypertension and its effect on (RAAS) of renin-angiotensin-aldosterone system. Methods 106 young and middle-aged patients with hypertension were randomly divided into observation group (53 cases) and control group (53 cases). The two groups were treated for 4 weeks and 2 courses were observed. Arterial blood pressure was monitored before and 8 weeks after treatment. Plasma renin active (PRA), angiotensin 鈪，

本文编号：2372080